Tenets of PTEN tumor suppression

被引：938
作者：
Salmena, Leonardo [1 ,2 ]
Carracedo, Arkaitz [1 ,2 ]
Pandolfi, Pier Paolo [1 ,2 ]
机构：
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Canc Genet Program, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol,Canc Genet Program, Boston, MA 02115 USA
来源：
CELL | 2008年 / 133卷 / 03期
关键词：
D O I：
10.1016/j.cell.2008.04.013
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Since its discovery as the elusive tumor suppressor gene at the frequently mutated 10q23 locus, PTEN has been identified as lost or mutated in several sporadic and heritable tumor types. A decade of work has established that PTEN is a nonredundant phosphatase that is essential for regulating the highly oncogenic prosurvival PI3K/AKT signaling pathway. This review discusses emerging modes of PTEN function and regulation, and speculates about how manipulation of PTEN function could be used for cancer therapy.
引用
收藏
页码：403 / 414
页数：12
相关论文
共 122 条
  • [11] RAS/ERK modulates TGFβ-regulated PTEN expression in human pancreatic adenocarcinoma cells
    Chow, Jimmy Y. C.
    Quach, Khai T.
    Cabrera, Betty L.
    Cabral, Jennifer A.
    Beck, Stayce E.
    Carethers, John M.
    [J]. CARCINOGENESIS, 2007, 28 (11) : 2321 - 2327
  • [12] Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein
    Chung, JH
    Ginn-Pease, ME
    Eng, C
    [J]. CANCER RESEARCH, 2005, 65 (10) : 4108 - 4116
  • [13] The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation
    Chung, Ji-Hyun
    Ostrowski, Michael C.
    Romigh, Todd
    Minaguchi, Takeo
    Waite, Kristin A.
    Eng, Charis
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 (17) : 2553 - 2559
  • [14] PTEN, a unique tumor suppressor gene
    Dahia, PLM
    [J]. ENDOCRINE-RELATED CANCER, 2000, 7 (02) : 115 - 129
  • [15] Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
    Davidson, Ben
    Hadar, Rivka
    Schlossberg, Anat
    Sternlicht, Tamar
    Slipicevic, Ana
    Skrede, Martina
    Risberg, Bjoern
    Florenes, Vivi Ann
    Kopolovic, Juri
    Reich, Reuven
    [J]. HUMAN PATHOLOGY, 2008, 39 (01) : 87 - 95
  • [16] SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles
    Déléris, P
    Bacqueville, D
    Gayral, S
    Carrez, L
    Salles, JP
    Perret, B
    Breton-Douillon, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (40) : 38884 - 38891
  • [17] Impaired Fas response and autoimmunity in Pten+/- mice
    Di Cristofano, A
    Kotsi, P
    Peng, YF
    Cordon-Cardo, C
    Elkon, KB
    Pandolfi, PP
    [J]. SCIENCE, 1999, 285 (5436) : 2122 - 2125
  • [18] Pten is essential for embryonic development and tumour suppression
    Di Cristofano, A
    Pesce, B
    Cordon-Cardo, C
    Pandolfi, PP
    [J]. NATURE GENETICS, 1998, 19 (04) : 348 - 355
  • [19] Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse
    Di Cristofano, A
    De Acetis, M
    Koff, A
    Cordon-Cardo, C
    Pandolfi, PP
    [J]. NATURE GENETICS, 2001, 27 (02) : 222 - 224
  • [20] Current development of mTOR inhibitors as anticancer agents
    Faivre, Sandrine
    Kroemer, Guido
    Raymond, Eric
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 671 - 688
12345678910